Skip to Main Content

Paper Details

Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study.
Gynecol Oncol
14
2022
Author NameAffiliation
Scott H KaufmannMayo Clinic
Scott H KaufmannMayo Clinic
Douglas A Levine
Douglas A Levine
Michael J BirrerWinthrop P Rockefeller Cancer Institute
  • 1 - 5

Datasets

Release 1.2